Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

China Biopharma IPOs Skyrocket In 2010 After Freeze Is Lifted

This article was originally published in PharmAsia News

Executive Summary

HONG KONG - The number of initial public offerings by pharmaceutical and biotech companies in China continued to rise in 2010, continuing a surge in IPOs that started in mid-2009

You may also be interested in...



India Draws Lessons From China To Help Foster Biotech Industry

India's Ministry of Science and Technology is exploring ways to spark innovation, from luring Indian scientists back from abroad to easing the path for government funding – PharmAsia News takes a closer look.

Fidelity Growth Partner Asia's Norman Chen On Being An Active Investor In China: An Interview With PharmAsia News (Part 2 of 2)

Fidelity Growth Partners Asia has made its name on several blockbuster investments in China. In the IT sector, Fidelity invested in Alibaba, China's leading e-commerce company. In healthcare, Fidelity was an early investor in China's leading CRO WuXi AppTec Inc. and remains one of its largest shareholders.

Fidelity Growth Partner Asia's Norman Chen On Being An Active Investor In China: An Interview With PharmAsia News (Part 2 of 2)

Fidelity Growth Partners Asia has made its name on several blockbuster investments in China. In the IT sector, Fidelity invested in Alibaba, China's leading e-commerce company. In healthcare, Fidelity was an early investor in China's leading CRO WuXi AppTec Inc. and remains one of its largest shareholders.

Related Content

Latest News
UsernamePublicRestriction

Register

SC076221

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel